Antibody Therapy Market by Antibody Type (Monoclonal Antibodies, Polyclonal Antibodies, Bispecific Antibodies, Conjugated Antibodies), by Therapy Type (Cancer Immunotherapy, Autoimmune Disease Therapy, Infectious Disease Treatment), by End-Use (Hospitals, Ambulatory Surgical Centers); Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Antibody Therapy Market was valued at USD 83.5 Billion in 2023 and will surpass USD 176.3 Billion by 2030; growing at a CAGR of 11.3% during 2024 - 2030.

The antibody therapy market is experiencing significant growth, driven by the increasing adoption of biologics for the treatment of various diseases, including cancer, autoimmune disorders, and infectious diseases. Antibody-based therapies have gained prominence due to their ability to target specific disease mechanisms with high precision, offering an advantage over traditional treatments. This market is characterized by rapid advancements in antibody technology, which has enabled the development of novel therapeutic antibodies, including monoclonal, bispecific, and conjugated antibodies. The increasing prevalence of chronic diseases, the rising demand for personalized medicine, and the growing number of regulatory approvals for antibody-based therapeutics are key factors contributing to the market’s expansion.

As the antibody therapy market evolves, innovation in antibody design and therapeutic applications continues to shape the industry. The market is also benefiting from ongoing research efforts to enhance the efficacy of antibody therapies and overcome challenges such as drug resistance and off-target effects. With the promise of more targeted and effective treatments, antibody therapies are poised to become a cornerstone in the management of complex diseases, positioning the market for continued growth in the coming years.

Monoclonal Antibodies Segment is Largest Owing to Extensive Use in Cancer Immunotherapy

Monoclonal antibodies (mAbs) dominate the antibody therapy market as the largest subsegment, primarily due to their extensive use in cancer immunotherapy. mAbs are laboratory-made molecules engineered to target specific antigens present on cancer cells, enhancing the body’s immune response to fight cancer. The growing prevalence of cancer and the success of monoclonal antibodies in treating various cancer types, such as breast, lung, and colorectal cancer, have significantly contributed to their dominance in the market.

Monoclonal antibodies are highly specific, offering the advantage of minimal side effects compared to traditional chemotherapy. Additionally, advances in mAb engineering have led to the development of targeted therapies, including immune checkpoint inhibitors and antibody-drug conjugates (ADCs), further expanding the use of mAbs in oncology. The continuous pipeline of mAb-based therapies under development for different types of cancer ensures that monoclonal antibodies will remain the largest segment in the antibody therapy market for the foreseeable future.

Cancer Immunotherapy Segment is Fastest Growing Owing to Increased Cancer Incidence

The cancer immunotherapy segment is the fastest-growing subsegment within the antibody therapy market, driven by the increasing incidence of cancer worldwide and the growing acceptance of immunotherapies. Cancer immunotherapy harnesses the body's immune system to fight cancer, and antibodies play a crucial role in this approach. Monoclonal antibodies targeting immune checkpoint inhibitors, such as PD-1/PD-L1 inhibitors, have revolutionized cancer treatment, offering significant survival benefits in various cancers.

The rapid growth of cancer immunotherapy is also fueled by the approval of new monoclonal antibody-based drugs and combination therapies by regulatory authorities, further expanding treatment options for cancer patients. With ongoing research into novel immunotherapy approaches and the rising demand for personalized medicine, the cancer immunotherapy segment is expected to continue to grow at an accelerated pace, making it the fastest-growing subsegment within the antibody therapy market.

Hospitals Segment is Largest End-User Owing to Advanced Treatment Infrastructure

Hospitals are the largest end-user segment in the antibody therapy market, driven by their advanced infrastructure and capacity to administer complex biologic therapies. Hospitals are at the forefront of providing cutting-edge treatments, including antibody therapies for cancer, autoimmune diseases, and infectious diseases. The availability of specialized medical professionals and sophisticated treatment facilities makes hospitals the primary setting for the administration of antibody-based therapeutics.

Moreover, hospitals often have the resources to manage the rigorous storage, handling, and administration requirements of antibody therapies. As the demand for biologic treatments continues to rise, hospitals remain the largest consumer of antibody therapies, particularly for high-cost and specialized treatments like monoclonal antibody-based cancer therapies. This trend is expected to persist as the role of biologics in modern medicine continues to expand, making hospitals the central hub for antibody therapy administration.

North America is Largest Region Owing to Strong Healthcare and Biotech Infrastructure

North America is the largest region in the antibody therapy market, driven by a robust healthcare infrastructure, a high concentration of biopharmaceutical companies, and significant investments in research and development. The United States, in particular, is a global leader in the development and commercialization of antibody-based therapies. The region benefits from a well-established regulatory environment, which has enabled the rapid approval and widespread adoption of innovative antibody therapeutics.

The large healthcare market in North America, coupled with a high rate of cancer incidence and autoimmune diseases, has fueled the demand for antibody-based therapies. The region also boasts advanced healthcare systems that support the administration of these therapies, further driving market growth. North America’s dominance is expected to continue, with increasing public and private sector investments in biotechnology and antibody drug development.

Competitive Landscape and Leading Companies

The antibody therapy market is highly competitive, with several major players leading the development of antibody-based therapies. Key companies in the market include Roche, Bristol-Myers Squibb, Merck & Co., Amgen, and AbbVie. These companies are at the forefront of developing monoclonal and bispecific antibodies for the treatment of cancer, autoimmune diseases, and infectious diseases.

The competitive landscape is characterized by ongoing innovation in antibody therapy design and the expansion of antibody applications across various therapeutic areas. Leading companies are focusing on improving the efficacy and safety profiles of their antibody-based treatments, as well as exploring combination therapies and novel delivery methods. Collaborations between biopharmaceutical companies, research institutions, and healthcare providers are also common, which help accelerate the development and commercialization of new antibody therapies. As the demand for antibody-based treatments continues to grow, these leading companies are well-positioned to maintain their leadership in the expanding antibody therapy market.

List of Leading Companies:

• AbbVie
• Amgen
• AstraZeneca
• Bristol-Myers Squibb
• Celltrion Healthcare
• Eli Lilly and Company
• Gilead Sciences
• GlaxoSmithKline
• Johnson & Johnson
• Merck & Co.
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Roche
• Sanofi

Recent Developments:

• Roche launched a new monoclonal antibody targeting a novel cancer antigen, showing promising results in clinical trials for solid tumors.
• Bristol-Myers Squibb received FDA approval for its bispecific antibody treatment for non-Hodgkin’s lymphoma, expanding its immuno-oncology portfolio.
• Merck & Co. announced the expansion of its antibody therapy research for autoimmune diseases, entering a strategic partnership with a leading biotech firm.
• Regeneron Pharmaceuticals introduced a new antibody therapy aimed at treating COVID-19, which demonstrated high efficacy in early trials.
• Amgen acquired a biotech company focused on antibody-drug conjugates, enhancing its pipeline for targeted cancer therapies.

Report Scope: